Health insurance company Oscar Health (NYSE:OSCR) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 23.2% year on year to $2.99 billion. On the other hand, the company’s full-year revenue guidance of$12.1 billion at the midpoint came in 0.5% above analysts’ estimates. Its GAAP loss of $0.53 per share was 6.8% below analysts’ consensus estimates. Is now the time to buy OSCR? Find out in our full research report (it’s free for active Edge members). Oscar Health (OSCR) Q3 CY2025 ...